MKS Instruments R&D increased by 5.2% to $81.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.7%, from $70.00M to $81.00M. Over 3 years (FY 2021 to FY 2025), R&D shows an upward trend with a 14.3% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $50.00M | $52.00M | $51.00M | $52.00M | $53.00M | $63.00M | $73.00M | $72.00M | $70.00M | $66.00M | $70.00M | $65.00M | $70.00M | $76.00M | $76.00M | $77.00M | $81.00M |
| QoQ Change | — | +4.0% | -1.9% | +2.0% | +1.9% | +18.9% | +15.9% | -1.4% | -2.8% | -5.7% | +6.1% | -7.1% | +7.7% | +8.6% | +0.0% | +1.3% | +5.2% |
| YoY Change | — | — | — | — | +6.0% | +21.2% | +43.1% | +38.5% | -2.8% | — | — | — | +0.0% | +15.2% | +8.6% | +18.5% | +15.7% |